10-Q: Albertsons Q3 Sales Up 1.9%, Digital Soars 21% Amid Legal Battles

Albertsons Companies reports a 1.9% increase in net sales and other revenue for Q3 fiscal 2025, driven by strong digital and pharmacy growth, despite ongoing legal challenges and a decline in net income.

Summary

• Net sales and other revenue increased 1.9% to $19,123.7 million for the 12 weeks ended November 29, 2025, compared to $18,774.5 million for the same period last year.
• Identical sales, excluding fuel, rose 2.4% in Q3 fiscal 2025.
• Digital sales grew 21% in Q3 fiscal 2025 compared to Q3 fiscal 2024.
• Loyalty membership increased 12% to 49.8 million.
• Net income decreased to $293.3 million ($0.55 per share) in Q3 fiscal 2025 from $400.6 million ($0.69 per share) in Q3 fiscal 2024.
• Adjusted net income was $390.3 million ($0.72 per share) in Q3 fiscal 2025, down from $420.3 million ($0.71 per share) in Q3 fiscal 2024.
• Adjusted EBITDA was $1,038.7 million in Q3 fiscal 2025, down from $1,065.1 million in Q3 fiscal 2024.
• Gross margin rate decreased to 27.4% from 27.9% year-over-year, primarily due to higher delivery and handling costs for digital sales and strong pharmacy sales (which carry a lower gross margin rate).
• Selling and administrative expenses as a percentage of net sales decreased to 24.9% from 25.1%, driven by sales leveraging of employee costs and lower merger-related costs.
• The merger agreement with Kroger was terminated on December 10, 2024, leading to a lawsuit filed by Albertsons against Kroger for willful breach and failure to secure regulatory approval, seeking damages and the $600 million termination fee.
• The company repurchased 64.1 million shares for $1,211.6 million during the first 40 weeks of fiscal 2025, including a $750 million accelerated share repurchase agreement.
• Long-term debt was refinanced with new senior unsecured notes: $600 million at 6.250% due 2033, $700 million at 5.500% due 2031, and $800 million at 5.750% due 2034.

Sentiment

Score: 4

Explanation: While the company demonstrated strong identical sales growth, particularly in digital and pharmacy, and made strategic moves in debt management and share repurchases, the significant decline in net income and Adjusted EBITDA, coupled with a lower gross margin rate and ongoing, costly legal battles, indicates a challenging period for profitability and operational efficiency. The legal uncertainties surrounding the Kroger merger termination and other litigations present a substantial financial and reputational overhang.

Positives

• Net sales and other revenue increased 1.9% to $19,123.7 million for the 12 weeks ended November 29, 2025.
• Identical sales, excluding fuel, increased 2.4% in Q3 fiscal 2025.
• Digital sales grew significantly by 21% in Q3 fiscal 2025 compared to Q3 fiscal 2024.
• Loyalty membership increased 12% to 49.8 million.
• Selling and administrative expenses as a percentage of Net sales and other revenue decreased by 33 basis points (excluding fuel) due to sales leveraging of employee costs and lower merger-related costs.
• Net gain on property dispositions and impairment losses was $1.2 million in Q3 fiscal 2025, compared to a $10.2 million loss in Q3 fiscal 2024.
• Successful refinancing of senior unsecured notes, extending maturities and managing debt profile.
• Increased share repurchase program authorization to $2.75 billion and executed a $750 million accelerated share repurchase agreement.
• Recorded a pension settlement gain of $26.8 million during the first 40 weeks of fiscal 2025.

Negatives

• Net income decreased to $293.3 million in Q3 fiscal 2025 from $400.6 million in Q3 fiscal 2024.
• Diluted net income per Class A common share decreased to $0.55 in Q3 fiscal 2025 from $0.69 in Q3 fiscal 2024.
• Adjusted net income decreased to $390.3 million in Q3 fiscal 2025 from $420.3 million in Q3 fiscal 2024.
• Adjusted EBITDA decreased to $1,038.7 million in Q3 fiscal 2025 from $1,065.1 million in Q3 fiscal 2024.
• Gross margin rate decreased to 27.4% from 27.9% (a 55 basis points decrease excluding fuel and LIFO) due to higher delivery and handling costs for digital sales and a higher mix of lower-margin pharmacy sales.
• Operating income decreased to $489.7 million in Q3 fiscal 2025 from $518.5 million in Q3 fiscal 2024.
• Income tax expense significantly increased to $84.4 million in Q3 fiscal 2025 from $14.5 million in Q3 fiscal 2024, primarily due to the absence of an $81.0 million discrete state income tax benefit recognized in the prior year.
• Cash flows provided by operating activities decreased to $1,649.6 million for the first 40 weeks of fiscal 2025 from $1,922.1 million for the same period last year.
• Interest expense, net, increased to $116.0 million in Q3 fiscal 2025 from $109.0 million in Q3 fiscal 2024, primarily due to higher average outstanding borrowings.
• Ongoing litigation with Kroger following the terminated merger, with Albertsons seeking damages and the $600 million termination fee, creating significant legal and financial uncertainty.
• Ongoing False Claims Act and Opioid litigation, with potential for substantial damages and legal costs.

Risks

• Changes in macroeconomic conditions such as rates of food price inflation or deflation, fuel and commodity prices, and macroeconomic uncertainty, including in international trade and current and potential future tariffs.
• Changes in consumer behavior and spending patterns resulting from macroeconomic conditions, including shifts in state and federal assistance programs.
• Changes in wage rates and the ability to negotiate acceptable contracts with labor unions, including the outcome of pending union negotiations.
• Changes in price of goods sold in stores and cost of goods used in food products, as well as limitations in the ability to provide certain services, due to changes in various state and federal government legislation, regulation, and executive orders.
• Uncertainty regarding the geopolitical environment.
• Inability to succeed in a competitive environment.
• Inability to execute on standalone business and value-creating strategies following the termination of the merger agreement with Kroger due to prolonged uncertainties and restrictions on the business during the pendency of the merger.
• Litigation in connection with the previously pending merger and the termination of the merger agreement, resulting in ongoing costs that the company may be required to pay in connection with the lawsuit against Kroger, or the inability to collect the $600 million termination fee from Kroger, and negative reactions from the financial markets and suppliers, customers, and associates as a result of the litigation.
• Ability to recruit and retain qualified or specialized associates who are critical to the success of the Customers for Life strategy.
• Failure to achieve productivity initiatives, including those related to artificial intelligence, unexpected changes in objectives and plans, inability to implement strategies, plans, programs and initiatives, or enter into strategic transactions, investments or partnerships in the future on terms acceptable to the company, or at all.
• Challenges with the supply chain.
• Operational and financial effects resulting from cyber incidents at the Company or at a third party, including outages in the cloud environment and the effectiveness of business continuity plans during a ransomware or other cyber incident.
• Changes in tax rates, tax laws, and regulations that directly impact the business or customers.
• Exposure to loss contingencies arising from pending or threatened litigation (e.g., False Claims Act, PBM, Opioid litigation) with substantial uncertainties regarding outcomes and potential material impact on results of operations or cash flows.

Future Outlook

The company anticipates significant sources of cash to meet its liquidity needs for the next 12 months and the foreseeable future, including cash on hand, cash flows from operating activities, and the ABL Facility. Estimated liquidity needs over the next 12 months are projected to be between $5.5 billion and $6.0 billion, covering various operational and financial obligations. The final settlement of the Accelerated Share Repurchase (ASR) agreement is expected in the first calendar quarter of 2026. The company is also evaluating the impact of recently issued accounting standards, with ASU 2023-09 not expected to have a material effect.

Management Comments

• "We continued to execute on our Customers for Life strategy, which is centered around driving customer growth and engagement through digital connection, expanding our Media Collective, enhancing the customer value proposition, modernizing capabilities through technology and driving transformational productivity."
• "Our digital investments are driving engagement, customer acquisition and retention."
• "Technology remains central to our long-term growth strategy, and this technology-first approach is enabling us to innovate faster, operate more efficiently and deliver greater value at lower cost."
• "Our capital allocation strategy balances investing for the future, strengthening our balance sheet and returns to shareholders through a combination of dividends and opportunistic share repurchases."
• "Based on current operating trends, we believe that we have significant sources of cash to meet our liquidity needs for the next 12 months and for the foreseeable future, including cash on hand, cash flows from operating activities and other sources of liquidity, including the ABL Facility."
• "We believe we have adequate cash flow to continue to maintain our current debt ratings and to respond effectively to competitive conditions."

Industry Context

Albertsons Companies operates in a highly competitive U.S. grocery retail market, facing macroeconomic pressures such as food price inflation and shifts in consumer spending. The company's strategic focus on digital growth (21% increase in digital sales) and expanding its loyalty program (49.8 million members) aligns with broader industry trends where retailers are heavily investing in omnichannel capabilities and customer engagement to maintain relevance and market share. The emphasis on technology, including AI-powered tools like AskAI and autonomous shopping assistants, reflects an industry-wide push towards modernization and personalized customer experiences. The strong performance in pharmacy sales suggests a robust demand in the healthcare retail segment, potentially outperforming other traditional grocery categories. However, the termination of the Kroger merger and subsequent litigation highlight the intense regulatory scrutiny and competitive landscape in the U.S. grocery sector, where large-scale consolidation faces significant hurdles.

Comparison to Industry Standards

• The 21% digital sales growth and 12% increase in loyalty members to 49.8 million demonstrate strong performance in key areas of modern grocery retail, comparable to efforts by industry leaders like Walmart, Target, and Amazon (Whole Foods) to enhance their digital and customer engagement platforms.
• The decline in net income and Adjusted EBITDA, coupled with a decrease in gross margin rate, suggests profitability pressures, potentially due to increased digital fulfillment costs, competitive pricing, and the lower margin profile of pharmacy sales, which is a common challenge for traditional grocers expanding into these segments.
• The substantial share repurchase program ($2.75 billion authorized, $1.21 billion executed) and consistent dividend payments ($0.45 per share for 40 weeks) reflect a commitment to shareholder returns, a standard practice for mature, cash-generating companies in the retail sector.
• The ongoing legal battles, including the terminated Kroger merger and the False Claims Act/Opioid litigation, represent significant legal and financial overhangs that, while not unique to Albertsons, are common for large, established companies with extensive operations and historical liabilities, and can divert management attention and resources.

Legal Proceedings

• **False Claims Act (FCA) Qui Tam Actions**: The company is defending two qui tam actions, *United States ex rel. Proctor v. Safeway* and *United States ex rel. Schutte and Yarberry v. SuperValu, New Albertson's, Inc., et al.*, alleging overcharging federal government healthcare programs. The Supreme Court reversed lower court rulings in both cases. The company prevailed at trial in *Schutte*, but relators have appealed the denial of a motion for a new trial on damages. A settlement conference was ordered for *Proctor*. Relators allege damages in excess of $100 million before trebling and excluding penalties in each case.
• **Pharmacy Benefit Manager (PBM) Litigation**: The company is a defendant in *Health Care Service Corp. et al. v. Albertsons Companies, LLC, et al.*, challenging prescription-drug prices. Prime Therapeutics LLC, a third-party defendant, was dismissed from the litigation on October 10, 2025. The case is currently scheduled to be ready for trial on or after February 18, 2027.
• **Opioid Litigation**: The company is a defendant in approximately 81 lawsuits filed by various plaintiffs alleging contribution to the national opioid epidemic. MDL cases are stayed except for 'bellwether' actions in Tarrant County (Texas) and Monterey County (California). Settlements were reached in New Mexico and Nevada for $21.5 million, paid by insurers. Active state court claims are in Dallas County (Texas), the State of Washington (trial scheduled May 4, 2026), and the City of Philadelphia (Pennsylvania, appeal awaiting ruling). The company has also received subpoenas from the U.S. Department of Justice and state Attorneys General regarding purported violations of the federal Controlled Substances Act and the FCA.
• **Termination of the Merger Agreement (with Kroger)**: The merger agreement was terminated on December 10, 2024, following injunctions. The company filed a lawsuit against Kroger in Delaware Court of Chancery on December 10, 2024, for willful breach and failure to secure regulatory approval, seeking damages and the $600 million termination fee. Kroger filed counterclaims. Trial is scheduled for October 19, 2026. The State of Washington awarded $28.4 million in attorneys' fees and costs against Kroger and the company, which is being appealed, with the company believing Kroger is solely responsible for payment.

Stakeholder Impact

• **Shareholders**: Impacted by decreased net income and EPS, but also by significant share repurchases ($1.21 billion) and consistent dividends ($0.45/share). The ongoing Kroger litigation and other legal proceedings create uncertainty and potential for significant financial outcomes (damages or termination fee).
• **Employees**: Business transformation costs include employee terminations. The 'Customers for Life' strategy and digital investments aim to enhance the business, potentially impacting roles and skill requirements. Retention programs were in place during the merger period.
• **Customers**: Benefit from digital investments (21% digital sales growth), loyalty program enhancements (12% member growth to 49.8 million), personalized promotions, and selective price investments.
• **Suppliers**: Potential negative reactions from suppliers due to merger litigation mentioned as a risk factor.
• **Creditors**: Debt refinancing activities (issuance of new senior unsecured notes, ABL facility amendment) impact the debt structure and maturity profile. The company believes it has adequate cash flow to maintain current debt ratings.

Next Steps

• Final settlement of the Accelerated Share Repurchase (ASR) agreement is expected in the first calendar quarter of 2026.
• Continued execution of the 'Customers for Life' strategy, focusing on digital connection, Media Collective expansion, customer value proposition enhancement, technology modernization, and transformational productivity.
• Ongoing defense against False Claims Act, PBM, and Opioid litigation.
• Trial for the lawsuit against Kroger in Delaware is scheduled for October 19, 2026.
• The PBM case is scheduled to be ready for trial on or after February 18, 2027.
• The State of Washington opioid matter is scheduled for trial on May 4, 2026.
• Appeal of the State of Washington's $28.4 million attorneys' fees and costs award.
• Awaiting court ruling on the City of Philadelphia opioid appeal.
• Awaiting decision on the motion for rehearing of the Dallas County opioid appeal denial.
• Anticipated additional contribution of $7.6 million to defined benefit pension plans for the remainder of fiscal 2025.
• Evaluation of new accounting standards (ASU 2024-03, ASU 2025-06).
• Next quarterly dividend payment of $0.15 per share on February 6, 2026, to stockholders of record as of January 23, 2026.

Key Dates

Recommendation

While Albertsons demonstrates strong operational execution in digital and loyalty, leading to identical sales growth, the decline in net income and Adjusted EBITDA, coupled with gross margin pressure, raises concerns about profitability. The company's aggressive share repurchase program and debt refinancing are positive for shareholder returns and balance sheet management, but the substantial legal overhang from the terminated Kroger merger and other litigations creates significant uncertainty and potential liabilities. A 'Hold' recommendation is appropriate given the mixed financial performance and the unresolved legal risks that could materially impact future financial results and valuation. Investors should await clearer outcomes from the litigations and evidence of sustained profitability improvements.

Keywords

Grocery retail, Supermarket, Digital sales, Loyalty program, Pharmacy, SEC filing, 10-Q, Financial results, Share repurchase, Debt refinancing, Litigation, Kroger merger, Albertsons